Literature DB >> 28523950

Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.

Alison Blackman1, Alyssa Boutin2, Alexei Shimanovsky3, William J Baker2, Nicholas Forcello4.   

Abstract

Asparaginase is a chemotherapeutic agent that is commonly used in combination with other medications for the treatment of acute lymphoblastic leukemia. An adverse effect of asparaginase includes hepatotoxicity, which can lead to severe liver failure and death. Several reports have documented successful treatment of asparaginase-induced hepatotoxicity using levocarnitine (l-carnitine) and vitamin B complex. Herein, we report a patient with acute lymphoblastic leukemia that experienced acute liver injury following pegaspargase administration. Our patient was successfully treated with l-carnitine and vitamin B complex for 8 days and achieved recovery of hepatic function. Furthermore, we review the current literature and provide a recommendation on a regimen that can be used as an option for the treatment of asparaginase-induced hepatic injury.

Entities:  

Keywords:  Hepatotoxicity; asparaginase; levocarnitine; pegasparagase; vitamin B

Mesh:

Substances:

Year:  2017        PMID: 28523950     DOI: 10.1177/1078155217710714

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  9 in total

1.  L-carnitine does not ameliorate asparaginase-associated hepatotoxicity in a C57BL6 mouse model.

Authors:  Yiwei Liu; Laura J Janke; Lie Li; Mary V Relling
Journal:  Leuk Lymphoma       Date:  2019-02-04

2.  Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.

Authors:  Sumit Gupta; Cindy Wang; Elizabeth A Raetz; Reuven Schore; Wanda L Salzer; Eric C Larsen; Kelly W Maloney; Len A Mattano; William L Carroll; Naomi J Winick; Stephen P Hunger; Mignon L Loh; Meenakshi Devidas
Journal:  J Clin Oncol       Date:  2020-04-10       Impact factor: 44.544

3.  Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.

Authors:  Natasha Kamal; Christopher Koh; Niharika Samala; Robert J Fontana; Andrew Stolz; Francisco Durazo; Paul H Hayashi; Elizabeth Phillips; Tongrong Wang; Jay H Hoofnagle
Journal:  Hepatol Int       Date:  2019-08-07       Impact factor: 6.047

4.  Dietary thiamine influences l-asparaginase sensitivity in a subset of leukemia cells.

Authors:  Rohiverth Guarecuco; Robert T Williams; Lou Baudrier; Konnor La; Maria C Passarelli; Naz Ekizoglu; Mert Mestanoglu; Hanan Alwaseem; Bety Rostandy; Justine Fidelin; Javier Garcia-Bermudez; Henrik Molina; Kıvanç Birsoy
Journal:  Sci Adv       Date:  2020-10-09       Impact factor: 14.136

Review 5.  Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy.

Authors:  Krishna R Juluri; Chloe Siu; Ryan D Cassaday
Journal:  Blood Lymphat Cancer       Date:  2022-05-30

6.  L-carnitine and Vitamin B Complex for PEG-L-asparaginase-Induced Hepatotoxicity.

Authors:  Sumant Arora; Jagpal Klair; Andrew M Bellizzi; Tomohiro Tanaka
Journal:  ACG Case Rep J       Date:  2019-08-28

7.  Natural Killer-Like T-Cell Lymphoma: A Rare Cause of Acute Liver Failure.

Authors:  Ishani Shah; Neil Vyas; Justin A Reynolds
Journal:  ACG Case Rep J       Date:  2019-07-17

8.  National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?

Authors:  Federico Lussana; Paola Minetto; Felicetto Ferrara; Sabina Chiaretti; Giorgina Specchia; Renato Bassan
Journal:  BMC Cancer       Date:  2020-10-02       Impact factor: 4.430

9.  Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.

Authors:  Rachael Schulte; Ashley Hinson; Van Huynh; Erin H Breese; Joanna Pierro; Seth Rotz; Benjamin A Mixon; Jennifer L McNeer; Michael J Burke; Etan Orgel
Journal:  Cancer Med       Date:  2021-09-16       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.